Cabaletta Bio, Inc.
CABANasdaq
$2.83
↑ +6.0%Jul 17 close · end-of-day
Price
1Y↑ +67.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$317.0M
Enterprise Value
$200.4M
P/E
—
P/S
—
P/B
3.1
EV/EBITDA
—
PEG
—
FCF Yield
-45.2%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$175.4M
Free Cash Flow (TTM)
-$143.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-169.8%
ROIC
—
Debt / Equity
—
Net Cash
$116.6M
Return 1Y
+68.5%
Company profile
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.
- CEO
- Steven Nichtberger
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- Pennsylvania
- Website
- www.cabalettabio.com
Management & directors
- Binder GwendolynPresident, Science & Tech.
- Chang David J.Chief Medical Officer
- Gavel SteveChief Commercial Officer
- Gerard MichaelGeneral Counsel
- Nichtberger StevenPresident & CEO
Roles derived from SEC Form 4 filings.
Earnings
CABA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.39↓ -45.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$33.8M | -$46.3M | -$54.1M | -$74.7M | -$125.1M | -$172.2M |
| Net income | -$33.3M | -$46.3M | -$53.0M | -$67.7M | -$115.9M | -$167.9M |
| Diluted EPS | — | -$1.80 | -$1.81 | -$1.65 | -$2.34 | -$2.10 |
| Operating cash flow | -$26.8M | -$34.1M | -$46.4M | -$53.5M | -$88.2M | -$131.1M |
| Free cash flow | -$27.4M | -$35.3M | -$48.8M | -$54.2M | -$90.4M | -$132.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$30.3M | -$33.0M | -$33.8M | -$37.1M | -$45.9M | -$46.6M | -$42.6M | -$44.3M |
| Net income | -$27.6M | -$30.6M | -$32.6M | -$35.9M | -$45.1M | -$44.9M | -$41.9M | -$43.5M |
| Diluted EPS | -$0.56 | -$0.62 | -$0.65 | -$0.71 | -$0.73 | -$0.44 | -$0.22 | -$0.39 |
| Operating cash flow | -$20.8M | -$20.3M | -$23.1M | -$30.8M | -$30.4M | -$34.5M | -$35.3M | -$42.6M |
| Free cash flow | -$21.6M | -$20.6M | -$23.5M | -$31.6M | -$30.6M | -$34.6M | -$35.5M | -$42.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-21 | Nichtberger Steven· President & CEO | Buy | 45,000 | $2.24 | $100,777.50 | filing |
| 2026-01-21 | Tomasello Shawn | Buy | 22,725 | $2.21 | $50,322.24 | filing |
| 2026-01-21 | Gavel Steve· Chief Commercial Officer | Buy | 22,170 | $2.27 | $50,215.05 | filing |
| 2026-01-21 | Simon Mark | Buy | 11,061 | $2.28 | $25,261.11 | filing |
| 2026-01-21 | Binder Gwendolyn· President, Science & Tech. | Buy | 11,312 | $2.19 | $24,763.10 | filing |
| 2026-01-21 | Chang David J.· Chief Medical Officer | Buy | 8,800 | $2.26 | $19,888.00 | filing |
| 2026-01-21 | Gerard Michael· General Counsel | Buy | 6,600 | $2.27 | $14,979.36 | filing |
| 2026-01-21 | Bollard Catherine | Buy | 4,405 | $2.27 | $9,982.17 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.